Interpretation of Science Sub-Journals!

February 22, 2021 News/bioon.
com" target="_blank">/---As people age, a normal brain protein called amyloid beta (Aβ) often begins to accumulate in the brain into harmful amyloid plaques.
This plaque may be the first step towards Alzheimer's dementia.
When they form around blood vessels in the brain---a symptom called cerebral amyloid angiopathy---, amyloid plaques also increase the risk of bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">stroke .

bioon.
com" target="_blank">bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">Stroke

Several antibodies that target amyloid plaques have been studied as experimental treatments for Alzheimer's disease.
Such antibodies may also have the potential to treat cerebral amyloid angiopathy, but they have not been evaluated in clinical trials.
However, all anti-amyloid antibodies that have successfully reduced amyloid plaques in Alzheimer's disease bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trials can also cause a worrying side effect: increased brain swelling and the risk of bleeding.

bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">Clinical Trials

Now, in a new study, researchers from Washington University St.
Louis School of Medicine and other research institutions have identified a kind of amyloid plaques in the brain tissue and blood vessels that can be removed in mice without increasing bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">cerebral hemorrhage.
Risky antibodies.
This antibody targets a minor component of amyloid plaques, apolipoprotein E (APOE).
These findings indicate that, as a treatment for Alzheimer's disease and cerebral amyloid angiopathy, removing harmful amyloid plaques is a potentially safer method.
The relevant research results were published in the journal Science Translational Medicine on February 17, 2021.
The title of the paper is "APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function".

bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">Cerebral hemorrhage

Picture from Science Translational Medicine, 2021, doi:10.
1126/scitranslmed.

abd7522.

bioon.

bioon.

Fortunately, these researchers have one such antibody on hand: an antibody called HAE-4, which targets a specific form of human APOE and triggers the clearance of amyloid plaques in brain tissue.
APOE is sparsely present in amyloid plaques.
In order to determine whether HAE-4 can also remove amyloid from cerebral blood vessels, they used genetically modified proteins that encode human amyloid and a type that is associated with a high risk of Alzheimer’s disease and cerebral amyloid angiopathy.
The APOE4 form of the gene in mice.
When such mice are about 6 months old, a large number of amyloid plaques appear in their brain tissue and cerebral blood vessels.

Experiments have shown that treating these mice with HAE-4 for 8 weeks can reduce amyloid plaques in brain tissue and cerebral blood vessels.
This treatment also significantly improves the ability of cerebral blood vessels to expand and contract on demand, which is an important indicator of blood vessel health.

Amyloid plaques in the blood vessels of the brain are dangerous because they can cause blockage or rupture, which can trigger a bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">stroke .
The researchers compared the number of cerebral hemorrhages in mice treated with HAE-4 or an anti-amyloid antibody called aducanumab used in a phase 3 bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trial to treat Alzheimer's disease for 8 weeks.
Minor bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">cerebral hemorrhage in these mice was at baseline level because of their bioon.
com/course_video/zhong-guo-ren-qun-ying-yang-he-yi-chuan-yin416058.
html">genetic susceptibility leading to the accumulation of amyloid in the blood vessels.
However, aducanumab significantly increased the amount of bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">cerebral hemorrhage in these mice , while HAE-4 did not.

bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">Stroke bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">Clinical Trials bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">Cerebral Hemorrhage bioon.
com/course_video/zhong-guo-ren-qun-ying-yang-he-yi-chuan-yin416058.
html">Genetic bioon.
com/tags/%E8%84%91%E5%87%BA%E8%A1%80/">Cerebral Hemorrhage

Further research showed that HAE-4 and aducanumab initially caused similar immune responses against amyloid plaques.
However, mice treated with this anti-APOE antibody (HAE-4) eliminated inflammation within two months, while mice treated with this anti-amyloid antibody (aducanumab) continued to have inflammation.

Holtzman said, “Some people have cerebral amyloid vascular disease, but have never had Alzheimer’s dementia, but they may suffer a bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">stroke .
The accumulation of amyloid in the cerebral blood vessels can be controlled by blood pressure and other things.
Management, but no specific treatment.
This study is exciting because it not only shows that we can treat this disease in animal models, but we may also be able to avoid the side effects of other anti-amyloid drugs Treatment under the circumstances.
” (Bioon.
com)

bioon.
com/tags/%E4%B8%AD%E9%A3%8E/">Stroke

References: 1.
Monica Xiong et al.
sciencemag.

org/content/13/581/eabd7522" target="_blank">APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function .
Science Translational Medicine, 2021, doi:10.

References: 1.
Monica Xiong et al.
sciencemag.
org/content/13/581/eabd7522" target="_blank">APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function .
Science Translational Medicine, 2021, doi:10.
1126/scitranslmed.
abd7522.
2.
Protein linked to Alzheimer's, strokes cleared from brain blood vessels
https://medicalxpress.
com/news/2021-02-protein-linked-alzheimer-brain-blood.
html sciencemag.
org/content/13/581/eabd7522" target="_blank">APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function